Caption Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.43M Sell
175,000
-960,000
-85% -$45.5M 0.04% 455
2025
Q4
$57.7M Buy
1,135,000
+685,000
+152% +$35M 0.4% 54
2025
Q3
$25M Buy
+450,000
New +$26.3M 0.19% 110
2025
Q2
Sell
-344,300
Closed -$23.9M 1760
2025
Q1
$23.9M Buy
344,300
+219,300
+175% +$18.1M 0.23% 72
2024
Q4
$10.8M Buy
+125,000
New +$13.5M 0.1% 176
2023
Q3
Sell
-60,000
Closed -$4.85M 1446
2023
Q2
$4.85M Hold
60,000
0.09% 295
2023
Q1
$4.77M Buy
+60,000
New +$4.25M 0.09% 243

Other funds holding NVO

Caption Management's NVO Position: Q1 2026 in Review

Caption Management reduced its Novo Nordisk (NVO) stake by 24% in Q1 2026, selling an estimated $927K and leaving 60,600 shares worth $2.23M. The position accounts for 0.01% of the portfolio, ranked #794.

Caption Management first reported a position in NVO in Q3 2018 and has held it in 8 quarters since. The position peaked at $8.75M in Q4 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Caption Management held 60,600 shares of Novo Nordisk worth $2.23M as of Q1 2026.
  • Caption Management sold 19,571 Novo Nordisk shares in Q1 2026, an estimated $927K.
  • Novo Nordisk made up 0.01% of Caption Management's portfolio in Q1 2026, its #794 holding.
  • Caption Management first reported a position in Novo Nordisk in Q3 2018 and has held it in 8 quarters since.
  • Caption Management's Novo Nordisk position peaked at $8.75M in Q4 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.